Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
-- Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments (Source: Abbott.com)
Source: Abbott.com - March 2, 2021 Category: Pharmaceuticals Source Type: news

Abbott Declares 389th Consecutive Quarterly Dividend
(Source: Abbott.com)
Source: Abbott.com - February 19, 2021 Category: Pharmaceuticals Source Type: news

Easterseals and the Abbott Fund Join Together to Advance Health Equity Through the Black Child Fund
- Support for the Easterseals Black Child Fund Will Advance Early Identification and Interventions Among Black Children to Reduce Health Disparities Often Experienced in Early Childhood (Source: Abbott.com)
Source: Abbott.com - February 1, 2021 Category: Pharmaceuticals Source Type: news

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales (Source: Abbott.com)
Source: Abbott.com - January 27, 2021 Category: Pharmaceuticals Source Type: news

Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
- Panbio ™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic (Source: Abbott.com)
Source: Abbott.com - January 26, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip ™ Device
- New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population (Source: Abbott.com)
Source: Abbott.com - January 20, 2021 Category: Pharmaceuticals Source Type: news

Abbott to Launch the NeuroSphere ™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
- New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data (Source: Abbott.com)
Source: Abbott.com - January 14, 2021 Category: Pharmaceuticals Source Type: news

Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW ™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution
- Abbott will complete the U.S. government order for 150 million BinaxNOW COVID-19 tests this week and will supply 30 million additional tests through March via a new government order (Source: Abbott.com)
Source: Abbott.com - January 12, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
- The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT ™ Alinity™ handheld device (Source: Abbott.com)
Source: Abbott.com - January 11, 2021 Category: Pharmaceuticals Source Type: news

Abbott Hosts Conference Call for Fourth-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - January 6, 2021 Category: Pharmaceuticals Source Type: news

As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner
- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout (Source: Abbott.com)
Source: Abbott.com - December 22, 2020 Category: Pharmaceuticals Source Type: news

Abbott to Present at J.P. Morgan Healthcare Conference
(Source: Abbott.com)
Source: Abbott.com - December 18, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients
- Abbott's HeartMate 3 ™ heart pump approved for use for pediatric patients battling advanced heart failure (Source: Abbott.com)
Source: Abbott.com - December 17, 2020 Category: Pharmaceuticals Source Type: news

Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform
- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes (Source: Abbott.com)
Source: Abbott.com - December 16, 2020 Category: Pharmaceuticals Source Type: news

Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
- SARS-CoV-2 IgG II Quant antibody test measures levels of IgG antibodies to help measure and understand a person's immune response (Source: Abbott.com)
Source: Abbott.com - December 15, 2020 Category: Pharmaceuticals Source Type: news

Abbott Develops New Pedialyte ® Hydration Solution to Help Support Immune Health
- New product contains zinc, prebiotics and vitamins B12, C and E (Source: Abbott.com)
Source: Abbott.com - December 14, 2020 Category: Pharmaceuticals Source Type: news

Abbott Increases Quarterly Dividend by 25%
- Increase reflects strength and sustainability of Abbott's diversified business (Source: Abbott.com)
Source: Abbott.com - December 11, 2020 Category: Pharmaceuticals Source Type: news

Abbott Launches First Optical Coherence Tomography Virtual Reality Training Program for Cardiologists
Virtual reality training improved cath lab staff learning engagement by 45% and knowledge retention by 72% (Source: Abbott.com)
Source: Abbott.com - December 9, 2020 Category: Pharmaceuticals Source Type: news

Nearly 2 out of 3 Cardiologists Concerned about Patient ’s Ability to Access Cardiovascular Care
- A survey, sponsored by Abbott, reveals three in four cardiologists worry the COVID-19 pandemic has restricted heart failure patients ’ ability to manage their condition (Source: Abbott.com)
Source: Abbott.com - December 2, 2020 Category: Pharmaceuticals Source Type: news

Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
(Source: Abbott.com)
Source: Abbott.com - December 2, 2020 Category: Pharmaceuticals Source Type: news

Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
- Abbott is committing $5 million over three years to the American Diabetes Association (ADA) to help close the health disparities gap for underserved diabetes communities, especially people of color and lower-income Americans (Source: Abbott.com)
Source: Abbott.com - November 18, 2020 Category: Pharmaceuticals Source Type: news

Abbott Launches the First Infant Formula in Canada with an Ingredient Identical in Structure to Immune Component Found in Breast Milk
(Source: Abbott.com)
Source: Abbott.com - November 17, 2020 Category: Pharmaceuticals Source Type: news

Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
- Abbott achieves top industry scores in governance/economic and social performance, earns more than triple the average industry score in its industry sector (Source: Abbott.com)
Source: Abbott.com - November 16, 2020 Category: Pharmaceuticals Source Type: news

Abbott Announces the U.S. Launch of the IonicRF ™ Generator for Use in Patients Living With Chronic Pain
-- Radiofrequency ablation is a minimally invasive procedure to deactivate nerves associated with pain for up to one year (Source: Abbott.com)
Source: Abbott.com - November 10, 2020 Category: Pharmaceuticals Source Type: news

Abbott Introduces Next-generation 3D Cardiac Mapping Platform in Europe and Australia
- The EnSite ™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures (Source: Abbott.com)
Source: Abbott.com - November 2, 2020 Category: Pharmaceuticals Source Type: news

Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip ™ Device
-- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 (Source: Abbott.com)
Source: Abbott.com - October 30, 2020 Category: Pharmaceuticals Source Type: news

Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent (Source: Abbott.com)
Source: Abbott.com - October 21, 2020 Category: Pharmaceuticals Source Type: news

Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
- New research from the University of Illinois, Urbana-Champaign, Abbott, and U.S. Air Force published in the journal Scientific Reports demonstrates that the right nutrition is directly linked to physical and cognitive performance in active duty men and women in the U.S. Air Force (Source: Abbott.com)
Source: Abbott.com - October 19, 2020 Category: Pharmaceuticals Source Type: news

New Late-Breaking Data Show Equivalent Outcomes with Shorter Durations of Anti-Clotting Drugs for XIENCE ™ Stent Patients with High Bleeding Risk
- Results from Abbott ’s XIENCE™ 28 and XIENCE 90 trials demonstrate non-inferiority of shorter courses of dual antiplatelet therapy in reducing the frequency of post-stenting death, heart attacks and severe bleeding compared with 12 months of dual antiplatelet therapy in patients with high bleeding risk (Source: Abbott.com)
Source: Abbott.com - October 15, 2020 Category: Pharmaceuticals Source Type: news

Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
- Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset (Source: Abbott.com)
Source: Abbott.com - October 12, 2020 Category: Pharmaceuticals Source Type: news

Abbott Releases ID NOW ™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
- Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset (Source: Abbott.com)
Source: Abbott.com - October 7, 2020 Category: Pharmaceuticals Source Type: news

Abbott Enrolls First Patient in Study to Investigate BurstDR ™ Stimulation to Treat Non-operative Low Back Pain
- Low back pain affects one in 10 Americans and often impacts the patient physically, emotionally and economically (Source: Abbott.com)
Source: Abbott.com - September 30, 2020 Category: Pharmaceuticals Source Type: news

Abbott's FreeStyle ® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people with diabetes (Source: Abbott.com)
Source: Abbott.com - September 28, 2020 Category: Pharmaceuticals Source Type: news

Abbott Receives CE Mark for Next-Generation MitraClip ™ Heart Valve Repair Device to Treat Mitral Regurgitation
- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology (Source: Abbott.com)
Source: Abbott.com - September 21, 2020 Category: Pharmaceuticals Source Type: news

Abbott Hosts Conference Call for Third-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - September 21, 2020 Category: Pharmaceuticals Source Type: news

Abbott Declares 387th Consecutive Quarterly Dividend
(Source: Abbott.com)
Source: Abbott.com - September 17, 2020 Category: Pharmaceuticals Source Type: news

Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes
- Abbott's Libre Sense Glucose Sport Biosensor, with CE Mark, is built upon the company's world-leading continuous glucose monitoring technology (Source: Abbott.com)
Source: Abbott.com - September 17, 2020 Category: Pharmaceuticals Source Type: news

Abbott Announces Start of Trial to Evaluate the New Esprit ™ BTK Drug-Eluting Resorbable Scaffold
- The LIFE-BTK trial will evaluate the company's new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) (Source: Abbott.com)
Source: Abbott.com - September 3, 2020 Category: Pharmaceuticals Source Type: news

Abbott's FreeStyle ® Libre 2 iCGM System Now Available to Medicare Beneficiaries
- U.S. Centers for Medicare& Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes (Source: Abbott.com)
Source: Abbott.com - September 1, 2020 Category: Pharmaceuticals Source Type: news

Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month
- Abbott's BinaxNOW ™ COVID-19 Ag Card is a rapid, reliable, highly portable, and affordable tool for detecting active coronavirus infections at massive scale (Source: Abbott.com)
Source: Abbott.com - August 26, 2020 Category: Pharmaceuticals Source Type: news

New Research Finds Physicians and Patients Point to Emerging Technology and Data as Central to Closing Treatment Gaps and Improving Vascular Health
(Source: Abbott.com)
Source: Abbott.com - August 19, 2020 Category: Pharmaceuticals Source Type: news

Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
- Recurrent irregular heartbeat--also known as atrial fibrillation--impacts more than 16 million people globally (Source: Abbott.com)
Source: Abbott.com - August 4, 2020 Category: Pharmaceuticals Source Type: news

Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
- Apple ‡ smartphone-compatible digital health tool fits within the company's broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders (Source: Abbott.com)
Source: Abbott.com - July 23, 2020 Category: Pharmaceuticals Source Type: news

Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations
- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales (Source: Abbott.com)
Source: Abbott.com - July 16, 2020 Category: Pharmaceuticals Source Type: news

Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
(Source: Abbott.com)
Source: Abbott.com - July 13, 2020 Category: Pharmaceuticals Source Type: news

Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
- Next-generation Gallant ™ implantable cardioverter defibrillator family of devices offers Bluetooth® capability for a more meaningful connection between patients and their doctors (Source: Abbott.com)
Source: Abbott.com - July 6, 2020 Category: Pharmaceuticals Source Type: news

Abbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems
- Companies partner to integrate Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management (Source: Abbott.com)
Source: Abbott.com - June 29, 2020 Category: Pharmaceuticals Source Type: news

New Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages
-- Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision (Source: Abbott.com)
Source: Abbott.com - June 26, 2020 Category: Pharmaceuticals Source Type: news

New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies
- New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies (Source: Abbott.com)
Source: Abbott.com - June 25, 2020 Category: Pharmaceuticals Source Type: news

Abbott Hosts Conference Call for Second-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - June 23, 2020 Category: Pharmaceuticals Source Type: news